Skip to main content

Table 6 The main studies describing the effectiveness/limitations of the HA 330 cartridge

From: Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls

  Huang et al. 2010 [56] Huang et al. 2013 [57]
Study design RCT RCT
Study population (n) 44 sepsis or septic shock patients 46 ALI/extra-pulmonary sepsis patients
EAA assessment
Prescribed dose HP for 2 h for 3 days HP for 2 h for 3 days
Survival • ICU mortality 12.5% in HA vs 45.0% in the controls (p = 0.02)
• Hospital mortality 37.5% in HA vs 50.0% in the controls (p = 0.81)
• 28-day mortality 45.8% in HA vs 55.0% in controls (p = 0.47)
• ICU mortality 24% in HA vs 57.14% in the controls (p = 0.02)
• 28-day mortality 28% in HA vs 66.7% in the controls (p = 0.009)
Length of ICU stay (days) 12.4 ± 3.1 in HA vs 19.5 ± 4.0 in controls (p = 0.03) 15.5 ± 4.0 in HA vs 19.4 ±  3.1 in controls (p = 0.04)
Hemodynamics Significant reduction in VP dose in the HA group vs increase in the control group (p = 0.01) Significant reduction in VP dose in the HA group vs increase in the control group (p = 0.032)
Other results Significant difference in IL-8 and IL-6 levels between the two groups at day 3 (p = 0.03 and 0.01, respectively) Significant difference in IL-1 and TNF-a in BAL fluid between the two groups (p = 0.02 and 0.04, respectively)
Safety • 1 patient with fever in the HA group
• Transient reduction in platelet counts in the HP group
  1. RCT randomized controlled trial, ALI acute lung injury, EAA endotoxin activity assay, HA hemadsorption, HP hemoperfusion, ICU intensive care unit, TNF tumor necrosis factor, BAL broncho-alveolar lavage, VP vasopressor, IL interleukin